Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA; IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; and IM-3050, a clinical-stage FAP-targeted radioligand therapy. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets. Immunome is seeking an experienced and collaborative Principal Scientist, Analytical Development and QC, Small Molecule to support our small molecule programs at various stages of development. The successful candidate will bring deep expertise in phase-appropriate small molecule analytical methods, development validation, transfer, and outsourced development models. Reporting to the Director, Analytical Development & QC, this individual-contributor role will develop complex analytical methods, resolve technical issues, work collaboratively with internal and external stakeholders and advance Immunome's oncology pipeline. In addition, this role will be part of a team to build and enhance internal analytical development capabilities, including method development, validation, and transfer processes. The ideal candidate will have a strong background in developing complex analytical methods spanning characterization and QC testing, experience in CDMO interactions, and familiarity with cGMP and authoring analytical documents for regulatory submissions.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Principal
Education Level
Ph.D. or professional degree